Trastuzumab Deruxtecan in HER2 -Mutant Non–Small-Cell Lung Cancer

🤖 Plain-English Summary

BACKGROUND: -mutant NSCLC have not been investigated extensively. Observed toxic effects were generally consistent with those in previously reported studies.

🔑 Key Findings

• METHODS: -mutant NSCLC that was refractory to standard treatment.
• The primary outcome was objective response as assessed by independent central review.
• Secondary outcomes included the duration of response, progression-free survival, overall survival, and safety.

🔗 Related Resources